<p>, /PRNewswire/ -- Gross Law Firm 向 <strong>ImmunityBio, Inc. (NASDAQ: IBRX)</strong> 的股東發佈以下通知。</p>
<p>在列出的訴訟期間內購買 IBRX 股票的股東被鼓勵與本事務所聯繫，以討論可能的首席原告任命。被任命為首席原告並不是參與任何賠償的必要條件。</p>
<p>聯繫我們：</p>
<p>https://securitiesclasslaw.com/securities/immunitybio-inc-loss-submission-form/?id=186861&amp;from=4</p>
<p>** 訴訟期間：**2026 年 1 月 19 日至 2026 年 3 月 24 日</p>
<p><strong>指控：</strong> 起訴書指控在訴訟期間，被告發布了實質性虛假和/或誤導性陳述，並/或未能披露以下內容：（1）被告 Soon-Shion 實質性誇大了 Anktiva 的能力；（2）因此，被告關於 ImmunityBio 的業務、運營和前景的陳述在所有相關時間都是實質性虛假和誤導的，且/或缺乏合理依據。</p>
<p><strong>截止日期：2026 年 5 月 26 日</strong> 股東不應延遲註冊此集體訴訟。請在此註冊您的信息： https://securitiesclasslaw.com/securities/immunitybio-inc-loss-submission-form/?id=186861&amp;from=4</p>
<p><strong>股東的下一步：</strong> 一旦您註冊為在上述時間段內購買 IBRX 股票的股東，您將被納入一個投資組合監控軟件，以便在案件生命週期內為您提供狀態更新。申請成為首席原告的截止日期為 2026 年 5 月 26 日。參與此案件對您沒有費用或義務。</p>
<p><strong>為什麼選擇 Gross Law Firm？</strong> Gross Law Firm 是一家全國知名的集體訴訟律師事務所，我們的使命是保護所有因欺詐、詐騙和非法商業行為而遭受損失的投資者的權利。Gross Law Firm 致力於確保公司遵循負責任的商業實踐並參與良好的企業公民行為。該事務所代表因公司發佈虛假和/或誤導性陳述或遺漏重要信息而導致公司股票人為膨脹而遭受損失的投資者尋求賠償。律師廣告。以往的結果並不保證類似的結果。</p>
<p><strong>聯繫方式：</strong></p>
<p>Gross Law Firm</p>
<p>15 West 38th Street, 12th floor</p>
<p>New York, NY, 10018</p>
<p>電子郵件：[email protected]</p>
<p>電話： (646) 453-8903</p>
<p>來源：Gross Law Firm</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTI2Jk5ld3NJdGVtSWQ9Tlk2NTY0MyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MjYwOTAwUFJfTkVXU19VU1BSX19fX19OWTY1NjQz?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTI2Jk5ld3NJdGVtSWQ9Tlk2NTY0MyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MjYwOTAwUFJfTkVXU19VU1BSX19fX19OWTY1NjQz"/></p>

IBRX

標普生物技術 ETF - SPDR

生物科技 ETF - VanEck Vectors

IBBQ

紐交所高增長板生物技術指數 ETF - First Trust

動態生物技術與基因組 ETF - Invesco

納斯達克生物科技指數 ETF - iShares Nasdaq

標普生物技術 3 倍做多 - Direxion

標普生物技術 3 倍做空 - Direxion

<p>Gross 律師事務所提醒 ImmunityBio, Inc.（納斯達克代碼：IBRX）股東，集體訴訟的主要原告截止日期為 2026 年 5 月 26 日。購買了 2026 年 1 月 19 日至 2026 年 3 月 24 日期間股票的股東，鼓勵註冊以爭取潛在的主要原告任命，原因是公司被指控發表誤導性聲明。參與此案件不產生任何費用</p>

<p>, /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of <strong>ImmunityBio, Inc. (NASDAQ: IBRX).</strong></p>
<div class="lb-trans"><p>, /PRNewswire/ -- Gross Law Firm 向 <strong>ImmunityBio, Inc. (NASDAQ: IBRX)</strong> 的股東發佈以下通知。</p>
</div><p>Shareholders who purchased shares of IBRX during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.</p>
<div class="lb-trans"><p>在列出的訴訟期間內購買 IBRX 股票的股東被鼓勵與本事務所聯繫，以討論可能的首席原告任命。被任命為首席原告並不是參與任何賠償的必要條件。</p>
</div><p>CONTACT US HERE:</p>
<div class="lb-trans"><p>聯繫我們：</p>
</div><p>https://securitiesclasslaw.com/securities/immunitybio-inc-loss-submission-form/?id=186861&amp;from=4</p>
<div class="lb-trans"><p>https://securitiesclasslaw.com/securities/immunitybio-inc-loss-submission-form/?id=186861&amp;from=4</p>
</div><p><strong>CLASS PERIOD:</strong> January 19, 2026 to March 24, 2026</p>
<div class="lb-trans"><p>** 訴訟期間：**2026 年 1 月 19 日至 2026 年 3 月 24 日</p>
</div><p><strong>ALLEGATIONS:</strong> The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) defendant Soon-Shion materially overstated Anktiva's capabilities; and (2) as a result, defendants' statements about ImmunityBio's business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all relevant times.</p>
<div class="lb-trans"><p><strong>指控：</strong> 起訴書指控在訴訟期間，被告發布了實質性虛假和/或誤導性陳述，並/或未能披露以下內容：（1）被告 Soon-Shion 實質性誇大了 Anktiva 的能力；（2）因此，被告關於 ImmunityBio 的業務、運營和前景的陳述在所有相關時間都是實質性虛假和誤導的，且/或缺乏合理依據。</p>
</div><p><strong>DEADLINE: May 26, 2026</strong> Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/immunitybio-inc-loss-submission-form/?id=186861&amp;from=4</p>
<div class="lb-trans"><p><strong>截止日期：2026 年 5 月 26 日</strong> 股東不應延遲註冊此集體訴訟。請在此註冊您的信息： https://securitiesclasslaw.com/securities/immunitybio-inc-loss-submission-form/?id=186861&amp;from=4</p>
</div><p><strong>NEXT STEPS FOR SHAREHOLDERS:</strong> Once you register as a shareholder who purchased shares of IBRX during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is May 26, 2026. There is no cost or obligation to you to participate in this case.</p>
<div class="lb-trans"><p><strong>股東的下一步：</strong> 一旦您註冊為在上述時間段內購買 IBRX 股票的股東，您將被納入一個投資組合監控軟件，以便在案件生命週期內為您提供狀態更新。申請成為首席原告的截止日期為 2026 年 5 月 26 日。參與此案件對您沒有費用或義務。</p>
</div><p><strong>WHY GROSS LAW FIRM?</strong> The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.</p>
<div class="lb-trans"><p><strong>為什麼選擇 Gross Law Firm？</strong> Gross Law Firm 是一家全國知名的集體訴訟律師事務所，我們的使命是保護所有因欺詐、詐騙和非法商業行為而遭受損失的投資者的權利。Gross Law Firm 致力於確保公司遵循負責任的商業實踐並參與良好的企業公民行為。該事務所代表因公司發佈虛假和/或誤導性陳述或遺漏重要信息而導致公司股票人為膨脹而遭受損失的投資者尋求賠償。律師廣告。以往的結果並不保證類似的結果。</p>
</div><p><strong>CONTACT:</strong></p>
<div class="lb-trans"><p><strong>聯繫方式：</strong></p>
</div><p>The Gross Law Firm</p>
<div class="lb-trans"><p>Gross Law Firm</p>
</div><p>15 West 38th Street, 12th floor</p>
<div class="lb-trans"><p>15 West 38th Street, 12th floor</p>
</div><p>New York, NY, 10018</p>
<div class="lb-trans"><p>New York, NY, 10018</p>
</div><p>Email: [email protected]</p>
<div class="lb-trans"><p>電子郵件：[email protected]</p>
</div><p>Phone: (646) 453-8903</p>
<div class="lb-trans"><p>電話： (646) 453-8903</p>
</div><p>SOURCE The Gross Law Firm</p>
<div class="lb-trans"><p>來源：Gross Law Firm</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjYwNTI2Jk5ld3NJdGVtSWQ9Tlk2NTY0MyZUcmFuc21pc3Npb25fSWQ9MjAyNjA1MjYwOTAwUFJfTkVXU19VU1BSX19fX19OWTY1NjQz" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=NY65643&amp;Transmission_Id=202605260900PR_NEWS_USPR_____NY65643&amp;DateId=20260526"/></p>

09:00 ETThe Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of May 26, 2026 in ImmunityBio, Inc. Lawsuit - IBRX

prnewswire

ImmunityBio

Invesco Nasdaq Biotechnology ETF

09:00 ET Gross 律師事務所提醒股東，ImmunityBio, Inc.訴訟的首席原告截止日期為2026年5月26日- IBRX